NDAQ:NBTX - Post Discussion
Post by
whytestocks on May 28, 2024 8:45pm
NANOBIOTIX Announces Presentation of new Data From Phase 1 I
JUST IN: $NBTX NANOBIOTIX Announces Presentation of new Data From Phase 1 Immunotherapy Program at the 2024 Annual Meeting of the American Society for Clinical Oncology Followed by an Investor Conference Call | BenzingaNew data from the completed dose escalation part and ongoing expansion part of Study 1100, an ongoing US Phase 1 study evaluating NBTXR3 followed...
NBTX - NANOBIOTIX Announces Presentation of new Data From Phase 1 Immunotherapy Program at the 2024 Annual Meeting of the American Society for Clinical Oncology Followed by an Investor Conference Call | Benzinga
Be the first to comment on this post